3 results
Approved WMORecruiting
Subjects randomized to the placebo treatment are unlikely to benefit from the study. However, OAB is not a life-threatening disease and it is not expected that a 12 to 15 week exposure to placebo treatment will have a negative impact on disease…
Approved WMORecruiting
To demonstrate safety and efficacy of Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DESin wide clinical use.
Approved WMORecruiting
The primary objective is to compare the effectiveness of ambroxol versus placebo on the MDS-UPDRS part III motor sub-score in the *practically defined OFF-medication state* in patients with moderate PD, carrying a GBA mutation. The hypothesis is…